JP2017500562A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500562A5 JP2017500562A5 JP2016538603A JP2016538603A JP2017500562A5 JP 2017500562 A5 JP2017500562 A5 JP 2017500562A5 JP 2016538603 A JP2016538603 A JP 2016538603A JP 2016538603 A JP2016538603 A JP 2016538603A JP 2017500562 A5 JP2017500562 A5 JP 2017500562A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- sample
- subject
- kit
- progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322094.2 | 2013-12-13 | ||
| GBGB1322094.2A GB201322094D0 (en) | 2013-12-13 | 2013-12-13 | Methods and compositions relating to alzheimers disease |
| PCT/GB2014/053692 WO2015087087A1 (en) | 2013-12-13 | 2014-12-12 | Biomarkers and methods relating to alzheimer's disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500562A JP2017500562A (ja) | 2017-01-05 |
| JP2017500562A5 true JP2017500562A5 (enExample) | 2018-01-25 |
| JP6803230B2 JP6803230B2 (ja) | 2020-12-23 |
Family
ID=50030903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538603A Active JP6803230B2 (ja) | 2013-12-13 | 2014-12-12 | アルツハイマー病に関するバイオマーカー及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12345717B2 (enExample) |
| EP (1) | EP3080609B1 (enExample) |
| JP (1) | JP6803230B2 (enExample) |
| CA (1) | CA2933398C (enExample) |
| GB (1) | GB201322094D0 (enExample) |
| WO (1) | WO2015087087A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504432D0 (en) * | 2015-03-17 | 2015-04-29 | Electrophoretics Ltd | Materials and methods for diagnosis and treatment of alzheimers disease |
| EP3242134A1 (en) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay for the diagnosis of a neurological disease |
| EP3499230A4 (en) * | 2016-08-09 | 2020-07-29 | Otsuka Pharmaceutical Co., Ltd. | Method for assisting diagnosis of alzheimer's disease using urine biomarker |
| AU2017376455A1 (en) * | 2016-12-13 | 2019-06-13 | Akili Interactive Labs, Inc. | Platform for identification of biomarkers using navigation tasks and treatments using navigation tasks |
| WO2019012671A1 (ja) * | 2017-07-13 | 2019-01-17 | 株式会社Ｍｃｂｉ | 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法 |
| CN111247595B (zh) | 2017-10-31 | 2024-07-23 | 通用电气健康护理有限公司 | 用于诊断认知疾病病理和/或结果的医疗系统 |
| GB201814807D0 (en) * | 2018-09-12 | 2018-10-24 | Univ Newcastle | Dementia Biomarkers |
| EP3909063A4 (en) * | 2019-01-09 | 2022-11-16 | Washington University | MULTIPLEX ASSAY AND METHODS OF USE THEREOF |
| US11860170B2 (en) * | 2019-05-16 | 2024-01-02 | Procisedx Inc. | Assay method for the detection of VCAM-1 and alpha-2-macroglobulin in blood |
| US11621087B2 (en) * | 2019-09-24 | 2023-04-04 | International Business Machines Corporation | Machine learning for amyloid and tau pathology prediction |
| JP2023505008A (ja) * | 2019-10-28 | 2023-02-08 | エージェント | アルツハイマー病の無症状期を診断するためのバイオマーカーおよびその使用 |
| KR20230004597A (ko) * | 2020-04-14 | 2023-01-06 | 주식회사 지뉴브 | 신경퇴행성질환 치료제에 대한 반응을 평가하기 위한 방법 및 조성물 |
| WO2022093274A1 (en) * | 2020-10-30 | 2022-05-05 | Baseline Global, Inc. | Methods, systems, and kits for prediction, detection, monitoring, and treatment of alzheimer's disease |
| US20220260559A1 (en) * | 2020-11-04 | 2022-08-18 | Seer, Inc. | Biomarkers for diagnosing alzheimer's disease |
| US20240077501A1 (en) * | 2020-12-28 | 2024-03-07 | Mcbi Inc. | Judgment supporting information generating method, judgment supporting information generating system, and information processing device |
| WO2022192019A1 (en) * | 2021-03-08 | 2022-09-15 | The Children's Medical Center Corporation | Methods for diagnosis and treatment of alzheimer's disease |
| CN115612728A (zh) * | 2021-07-16 | 2023-01-17 | 深圳先进技术研究院 | 一种神经退行性疾病标志物及其应用 |
| CN114705866A (zh) * | 2022-03-14 | 2022-07-05 | 上海市精神卫生中心（上海市心理咨询培训中心） | 基于血液的遗忘型轻度认知损害早期诊断外周血蛋白标志物、应用及其医疗辅助诊断系统 |
| EP4549945A1 (en) * | 2022-06-28 | 2025-05-07 | Mcbi Inc. | Assessment-supporting information generating method, assessment-supporting information generating system, and information processing device |
| WO2024195825A1 (ja) * | 2023-03-22 | 2024-09-26 | 味の素株式会社 | 血中メタボロームによる脳萎縮の評価方法 |
| CN116790745A (zh) * | 2023-07-03 | 2023-09-22 | 复旦大学 | 阿尔茨海默病临床前期疾病转化的标志物及其筛选方法 |
| WO2025057945A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人三重大学 | 対象が脳アミロイド血管症を有するかを判定するための方法、アルツハイマー病に対する抗アミロイドβ抗体による治療の副作用のリスクまたは存在を判定するための方法、およびアルツハイマー病に対する抗アミロイドβ抗体による治療の対象を選択するための方法、ならびにそのための組成物およびキット |
| CN117538545B (zh) * | 2024-01-09 | 2024-07-05 | 上海众启生物科技有限公司 | 一种用于阿尔茨海默症检测的蛋白抗原组合及应用 |
| WO2025168038A1 (en) * | 2024-02-07 | 2025-08-14 | Kunming Institute Of Zoology, Chinese Academy Of Sciences | Methods and compositions for ameliorating impairment of regenerative and cognitive function |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| AU2002335965A1 (en) | 2001-11-23 | 2003-06-10 | Syn.X Pharma, Inc. | Pedf biopolymer markers predictive of alzheimers disease |
| DE60333608D1 (de) | 2002-08-23 | 2010-09-09 | Bayer Schering Pharma Ag | Biomarker zur Diagnose von Alzheimer |
| PT2211183E (pt) | 2003-11-19 | 2013-05-31 | Satoris Inc | Método para diagnosticar e monitorizar a doença de alzheimer |
| GB0421639D0 (en) | 2004-09-29 | 2004-10-27 | Proteome Sciences Plc | Methods and compositions relating to alzheimer's disease |
| DE102010026238B4 (de) * | 2010-06-29 | 2012-08-16 | Schuberth Gmbh | Schutzhelm und Tragkorb für einen Schutzhelm |
-
2013
- 2013-12-13 GB GBGB1322094.2A patent/GB201322094D0/en not_active Ceased
-
2014
- 2014-12-12 JP JP2016538603A patent/JP6803230B2/ja active Active
- 2014-12-12 WO PCT/GB2014/053692 patent/WO2015087087A1/en not_active Ceased
- 2014-12-12 US US15/104,149 patent/US12345717B2/en active Active
- 2014-12-12 CA CA2933398A patent/CA2933398C/en active Active
- 2014-12-12 EP EP14830849.7A patent/EP3080609B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jacobs et al. | Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau | |
| Choi et al. | Increased plasma levels of lipocalin 2 in mild cognitive impairment | |
| Zhang et al. | Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease | |
| Hesse et al. | Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke | |
| Teunissen et al. | Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics | |
| Roche et al. | Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers | |
| Awad et al. | Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis | |
| Zhang et al. | A comprehensive map and functional annotation of the normal human cerebrospinal fluid proteome | |
| Romeo et al. | CSF proteome: a protein repository for potential biomarker identification | |
| Hardy-Sosa et al. | Diagnostic accuracy of blood-based biomarker panels: a systematic review | |
| Nielsen et al. | Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies | |
| Shen et al. | Proteomics analysis of blood serums from Alzheimer’s disease patients using iTRAQ labeling technology | |
| JP2016533499A5 (enExample) | ||
| Popp et al. | Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer’s disease | |
| Bednarska-Makaruk et al. | Homocysteine metabolism and the associations of global DNA methylation with selected gene polymorphisms and nutritional factors in patients with dementia | |
| Cutler et al. | Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium‐derived factor: two novel biomarkers of Alzheimer's disease in human plasma | |
| WO2015027276A1 (en) | Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases | |
| Akuffo et al. | The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone | |
| WO2016146783A1 (en) | Materials and methods for diagnosis and treatment of alzheimer's disease | |
| Nakajima et al. | Leucine-rich α-2-glycoprotein is a marker for idiopathic normal pressure hydrocephalus | |
| US20110143380A1 (en) | Alzheimer's disease biomarkers and methods of use | |
| Dong et al. | The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics | |
| JP2018516849A5 (enExample) | ||
| Davidsson et al. | Proteome studies of CSF in AD patients | |
| Lleó et al. | Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders? |